Bringing Groundbreaking Treatments to Patients with Psychiatric and Neurodegenerative Diseases

Unleashing unique properties and biological effects of Noble gases for treatment of PTSD, Autism, Dementia

Combining revolutionary portable inhalation device with a safe therapeutic

Accelerated pathway of clinical development

Nobilis Therapeutics is a clinical stage biotechnology company developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 2500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

News Feed

Twitter Feed

Nobilis Therapeutics @NobilisTx
Nobilis Therapeutics Announces FDA Clearance of IND to Start Phase 2b Trial of NBTX-001 for Treatment of PTSD https://t.co/S7LJTHBzL9
h J R
Nobilis Therapeutics @NobilisTx
Xenon and Autism - our animal study shows promise. https://t.co/eKov66zLGY
h J R
Nobilis Therapeutics @NobilisTx
Nobilis Therapeutics publishes a case report describing a successful treatment of a patient with severe PTSD. https://t.co/Npf1cWnFn0
h J R
Nobilis Therapeutics @NobilisTx
We have been saying this all along: https://t.co/vCay9lC3Kh
h J R